Tags

Type your tag names separated by a space and hit enter

New molecular targets for antianxiety interventions.
J Clin Psychiatry. 2003; 64 Suppl 3:28-35.JC

Abstract

Recent advances in neuroscience and understanding in the etiology of anxiety have led researchers to new targets for treatments that are proving to be at least as effective as benzodiazepines, which have been the traditional treatment for anxiety for over 40 years. The gamma-aminobutyric acid (GABA) system has long been targeted in anxiety interventions via benzodiazepines, but better understanding of its role in anxiety disorders has led to the development of partial benzodiazepine-GABA receptor antagonists and agents that target specific subunits of the GABA-A receptor and that manipulate GABA levels. The recognition that antidepressants are effective in anxiety even in nondepressed patients has caused researchers to develop antianxiety agents that affect the serotonin and norepinephrine systems. Other neurotransmitter systems such as corticotropin-releasing factor and substance P appear to be abnormally regulated in patients with anxiety disorders, so antagonists of these neurotransmitters may prove to be beneficial anxiolytics. Meanwhile, antistress and antianxiety effects through neurogenesis may be possible with the use of agents that decrease glutamate neurotransmission, such as metabotropic glutamate receptor agonists. Finally, the stimulation of neurotrophic factors, such as brain-derived neurotrophic factor, which appears to enhance neurogenesis, may also prove to have anxiolytic effects.

Authors+Show Affiliations

Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

12662131

Citation

Gorman, Jack M.. "New Molecular Targets for Antianxiety Interventions." The Journal of Clinical Psychiatry, vol. 64 Suppl 3, 2003, pp. 28-35.
Gorman JM. New molecular targets for antianxiety interventions. J Clin Psychiatry. 2003;64 Suppl 3:28-35.
Gorman, J. M. (2003). New molecular targets for antianxiety interventions. The Journal of Clinical Psychiatry, 64 Suppl 3, 28-35.
Gorman JM. New Molecular Targets for Antianxiety Interventions. J Clin Psychiatry. 2003;64 Suppl 3:28-35. PubMed PMID: 12662131.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New molecular targets for antianxiety interventions. A1 - Gorman,Jack M, PY - 2003/3/29/pubmed PY - 2003/4/23/medline PY - 2003/3/29/entrez SP - 28 EP - 35 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 64 Suppl 3 N2 - Recent advances in neuroscience and understanding in the etiology of anxiety have led researchers to new targets for treatments that are proving to be at least as effective as benzodiazepines, which have been the traditional treatment for anxiety for over 40 years. The gamma-aminobutyric acid (GABA) system has long been targeted in anxiety interventions via benzodiazepines, but better understanding of its role in anxiety disorders has led to the development of partial benzodiazepine-GABA receptor antagonists and agents that target specific subunits of the GABA-A receptor and that manipulate GABA levels. The recognition that antidepressants are effective in anxiety even in nondepressed patients has caused researchers to develop antianxiety agents that affect the serotonin and norepinephrine systems. Other neurotransmitter systems such as corticotropin-releasing factor and substance P appear to be abnormally regulated in patients with anxiety disorders, so antagonists of these neurotransmitters may prove to be beneficial anxiolytics. Meanwhile, antistress and antianxiety effects through neurogenesis may be possible with the use of agents that decrease glutamate neurotransmission, such as metabotropic glutamate receptor agonists. Finally, the stimulation of neurotrophic factors, such as brain-derived neurotrophic factor, which appears to enhance neurogenesis, may also prove to have anxiolytic effects. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/12662131/New_molecular_targets_for_antianxiety_interventions_ L2 - http://www.psychiatrist.com/jcp/article/pages/2003/v64s03/v64s0305.aspx DB - PRIME DP - Unbound Medicine ER -